Trade Ideas

Traders Sentiment

Technical Summary



New York Times business news - Jan. 18

Jan 18 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - BlackRock Inc BLK.N Chief Executive Officer Larry Fink delivered his words in annual letters on Tuesday that have drawn remarkable attention, but also criticism from all corners:

Pfizer to boost 19 pill production with French deal

PARIS, Jan 17 (Reuters) - Pfizer PFE.N will add a production facility for its antiviral COVID-19 pill in France as part of a plan to invest 520 million euros ($594 million) in the country over the next five years, the U.S. drugmaker said on Monday. The decision is part of Pfizer's strategy to boost global production of the pill, paxlovid, which was

Financial Times - Jan 17

Jan 17 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines Horta-Osório resigns as Credit Suisse chair over COVID-19 breaches Link GSK and Pfizer hold out for 60 bln pounds bid for consumer health unit Link BBC licence fee to be abolished in 2

Pfizer says it applied for Japan gov't approval for oral 19 drug

TOKYO, Jan 14 (Reuters) - U.S. drugmaker Pfizer Inc PFE.N said on Friday it has applied for Japanese government approval for its oral COVID-19 treatment. The application is based on global Phase II/III trials that Japan was part of, Pfizer said in a statement. With COVID-19 cases surging again, Japan is betting heavily on oral treatments to keep se

Pfizer says it applied for Japanese govt approval for oral 19 drug

TOKYO, Jan 14 (Reuters) - Pfizer Inc PFE.N said on Friday it applied for Japanese government approval for its oral COVID-19 treatment. Japanese Prime Minister Fumio Kishida said last month he spoke with Pfizer CEO Albert Bourla to secure 2 million doses of Pfizer's antiviral pill. Reporting by Rocky Swift; Editing by Jacqueline Wong


Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.